News

Euclid Vision Announces Acquisition of Visionary Optics

Euclid Vision Corp., a global leader in advanced orthokeratology and proactive myopia management initiatives, is pleased to announce its acquisition of Visionary Optics, a specialty scleral contact lens design and distribution pioneer. The acquisition signifies Euclid’s recognition of the value of joining forces with Visionary Optics, the only company in the US that concentrates almost exclusively on scleral contact lenses. The union of these two companies increases each establishment’s ability to provide comprehensive specialty contact lens care to more patients globally.

“We are excited about joining forces with Visionary Optics. This union opens exciting opportunities for cross-company collaboration and innovation,” said Joseph Boorady, Euclid President and CEO. “Visionary Optics, with its best-in-class scleral lens innovations and world class customer service, is a great match for the Euclid portfolio. Having market leading technologies in two of the fastest growing specialty contact lens markets — Ortho-K and scleral lenses — positions us to better serve our customers and their patients.”

Euclid and Visionary Optics share many of the same cultural values, such as a dedication to professional education, strong partnerships with eye care professionals, and market savvy product innovation. Each company will retain their unique individual brand, while being perfectly positioned to reap the benefits of shared future endeavors.

“This is an incredible opportunity for Visionary Optics to work with a partner who can help take our business and technology to the next level, while also maintaining the key foundational aspects of what has fueled our success including our customer-driven corporate culture and high-tech research orientation,” said Donald Sanders, MD, PhD Visionary Optics President and CEO.

Euclid and Visionary Optics understand that clinicians partner with companies that not only offer unparalleled lens design and the highest-level of advanced manufacturing, but those that also provide exceptional customer service. “Expert customer service is critical to the success of the clinicians who work with us, and we pride ourselves on the level of expertise for which our customer service team is known,” said Dr. Sanders. “As we unite with Euclid, preserving these team values are integral to maintaining our role as a leader in scleral lens design and distribution. Thus, our customers can count on the same great service they are used to with Visionary Optics.”

Recent News

10/23/2026

PAK BioSolutions and iBET Advance Integrated Continuous AAV8 Purification

PAK BioSolutions today announced the publication of a peer-reviewed study on integrated, continuous purification of adeno-associated virus serotype 8 (AAV8) using the PAK PD™ Process Development Scale Continuous Purification System. Conducted in collaboration with iBET – Instituto de Biologia Experimental e Tecnológica, the study, “Streamlining AAV8 Purification with Cyclic Integrated Capture–Polishing Chromatography,” was published in …

10/22/2026

Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020

Eli Lilly and Company (NYSE: LLY) broke ground today on a new $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County, one of 10 new U.S. manufacturing sites announced since 2020 and one of five among them that will produce active pharmaceutical ingredients (API). As part of the company’s more than $50 …

10/21/2026

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. …